1. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 31 October 2016
2. Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms
3. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
4. Caveney E, Turner JR. White paper. A review of FDA guidance: understanding the FDA guidance on assessing cardiovascular risks for new antidiabetic therapies [Internet]. Available from http://www.quintiles.com/library/white-papers/new-fda-guidance-on-antidiabetic-therapies. Accessed 31 October 2016
5. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet], 2012. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 3 November 2016